Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

BMN 270 is one of the most important drugs in Biomarin's research pipeline and key driver of future revenue and earnings.

Anavex Alzheimer's Drug Plays Losing Game Against Placebo Effect

Anavex Alzheimer's Drug Plays Losing Game Against Placebo Effect

A small group of Alzheimer's patients treated with Anavex 2-73 are exhibiting signs of memory loss, faltering cognition and inability to take care of themselves over time.

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

When your top line declines, it's harder to convince investors it's okay to wait years see if a partnership in an early-stage biotech company delivers a home-run drug.

Celgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet

Celgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet

Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.